Precision
Medicine.

Dynamic personalized tests provide clinicians with early actionable data from the patient's own biological message systems.

Discover More

Precision
Diagnostics.

One test, one RNA Signature with strong performance on all
clinical metrics.

Discover More

Leading
Edge Precision.

Artificial intelligence-assisted analysis of selected signals provides the most relevant information for ALL transplant patients.

Discover More

Tutivia ™

A precise multi-gene RNA signature developed through AI techniques to provide an early warning blood-based assay that can detect all types of acute rejection, preceding traditional markers. Clinicians can use this test for both high risk or low risk individuals from the first week post-transplant and during follow-ups, regardless of delayed graft function, multiple transplants, or BK nephropathy.

Actionable Risk Scores for Every Patient

Verici Dx Expert's Corner

Visit our Expert's Corner page to explore two compelling case studies showcasing Tutivia's clinical utility–one on managing patients with delayed draft function and the other in managing patients with BK Virus.

Click here to explore.

Where Complexity Meets Clarity

VericiDx is excited to announce that our Tutivia validation study is available as open access in the March American Journal of Transplantation.

To access the Tutivia validation study click here.

Videos

Tutivia in Kidney Transplantation

Curious about RNA in biomarkers? Tune into our fire side chat led by transplant nephrologists discussing the role of biomarkers in transplant care and introducing the next generation of risk assessment - Tutivia.

Speakers:
  • Dr. Zahraa Hajjiri, MD
    Medical Director of Transplant Nephrology,
    University of Illinois Chicago
  • Dr. M. Javeed Ansari, MD, MRCP
    Associate Professor of Medicine, Division of Nephrology,
    Associate Professor of Surgery, Division of Organ Transplantation,
    Northwestern University Feinberg School of Medicine
  • Prince Mohan Anand MD, FACP, FASN, FAST
    Director of Transplant Services,
    MUSC Mid-Carolinas

Coffee & Cases Episode 3: IOTA - Impact & Implications

Join us over a cup of coffee for our next episode, where our two distinguished speakers will break down the latest changes in transplantation. They'll explore the potential impact of IOTA and discuss the clinical implications of these updates.

Coffee & Cases Episode 2: Clinical Management of BK

In this episode of Coffee & Cases, Dr. Ansari, Transplant Nephrologist at Northwestern University, will be walking us through the clinical management of BK virus in transplant patients.

Coffee & Cases Episode 1: Delayed Graft Function

Coffee & Cases is a series where medical experts discuss real-world cases over a cup of coffee. In Episode 1, Dr. Zahraa Hajjiri, the Medical Director of the Transplant Program at the University of Illinois at Chicago, explores Delayed Graft Function, a crucial topic in transplant medicine. This episode provides valuable insights into its causes, challenges, and management strategies.

Posters & Papers

2025 WTC Poster:
Utility of Rejection Biomarker Tutivia in Managing Kidney Transplant Recipients at Risk of BK Nephropathy

This study analyzed the utility of Tutivia – a novel gene expression-based biomarker test of rejection in evaluating the risk of rejection in the setting of lowered immunosuppression in kidney transplant recipients with BKVAN or at risk of BKVAN.

2025 WTC Poster:
The Role of Gene Expression Profile in Predicting Acute Rejection

This analysis aimed to identify the relationship between Tutivia, incidence of allograft rejection and the overall stability of renal allograft function.

2025 CEoT Poster

Performance of Tutivia RNA Signature in Kidney Transplant Patients with Multi-organ and Previous Failed Kidney Transplants

Tutivia Validation Study

Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection
Tutivia Delivers

Please provide some basic information to access this content.